Med Discovery participates in successful ISK 2009 conference
Med Discovery was major sponsor and presenter at the 3rd International Symposium on Kallikreins and Kallikrein-related Peptidases in Munich
The 3rd International Symposium on Kallikreins and Kallikrein-related Peptidases took place in Munich on August 30-September 2, 2009. This bi-annual meeting is the only scientific meeting exclusively focused on the kallikreins, and gathers together scientists from all the principal laboratories in the field. The meeting was a great success with about 150 attendees from all over the world. Med Discovery had the privilege to be a major sponsor, and to make both podium and poster presentations on the exciting advances made in the kallikrein field by the company.
“This meeting represented a major milestone for Med Discovery. Since the company was founded, researchers around the word have made fantastic progress showing clearly that kallikreins are involved in the pathophysiology of different diseases such as prostate cancer and skin disorders, both therapeutic areas in which we are active” said Christoph Kündig, Director of R&D. “The choice that we made 7 years ago to develop antiprotease compounds against kallikreins seems clearly vindicated. We are very happy for our investors and people who believed in and supported this project. It is also encouraging to see that Med Discovery continues to maintain its lead on the commercial development of recombinant serpins to target these disease areas. 2010 will be a key year for the field since Med Discovery will be the first to assess a compound against novel kallikrein targets in the treatment of a disease”
For further information: http://www.iks2009.de/